 SEATTLE, June 1, 2021 PRNewswire -- CTI BioPharma Corp. Nasdaq: CTIC today announced that the U.S. Food and Drug Administration FDA has accepted its New Drug Application NDA for pacritinib as a treatment for myelofibrosis patients with severe thrombocytopenia platelet counts less than 50 x 109L, with the NDA being granted Priority Review. The Prescription Drug User Fee Act PDUFA target action date is November 30, 2021. 